Abstract
Background
Neuroblastoma (NBL) is an extracranial malignant tumor in children deriving from the neural crest in the sympathetic nervous system. Although various immunotherapy interventions have made significant breakthroughs in many adult cancers, the efficacy of these immunotherapies was still limited in NBL. NBL has low immunogenicity which results in a lack of tumor-infiltrating T lymphocytes in the tumor microenvironment (TME). Moreover, tumor cells can wield many immune evasion strategies both in the TME and systemically to impede lymphocyte infiltration and activation. All these factors hamper the anti-tumor effects of CD8+ T cells during immunotherapy and the levels of infiltrating CD8+ T cells correlate with therapy response.
Materials and methods
In this study, we utilized multidimensional bioinformatic methods to establish a risk model based on CD8+ T cells -related genes (CD8+ TRGs).
Results
We obtained 33 CD8+ TRGs with well-predictive ability for prognosis in both GSE49711 and E-MTAB-8248 cohorts. Then, 12 CD8+ TRGs including HK2, RP2, HPSE, ELL2, GFI1, SLC22A16, FCGR3A, CTSS, SH2D1A, RBP5, ATF5, and ADAM9 were finally identified for risk model construction and validation. This model revealed a stable performance in prognostic prediction of the overall survival (OS) and event-free survival (EFS) in patients with NBL. Additionally, our research indicated that the immune and stromal scores, immune-related pathways, immune cell infiltration, the expression of major histocompatibility complex (MHC) and immune checkpoint molecules, immunotherapy response, and drug susceptibility revealed significant differences between high and low-risk groups.
Conclusions
According to our analyses, the constructed CD8+ TRGs-based risk model may be promising for the clinical prediction of anti-tumor therapy responses and prognoses in NBL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data used to support the findings of this study are available from the corresponding author on reasonable request.
Abbreviations
- NBL:
-
Neuroblastoma
- TME:
-
Tumor microenvironment
- CD8+ TRGs:
-
CD8+ T cells -related genes
- OS:
-
Overall survival
- EFS:
-
Event-free survival
- MHC:
-
Major histocompatibility complex
- CTLs:
-
Cytotoxic T lymphocytes
- GEO:
-
Gene expression omnibus
- GO:
-
Gene ontology
- KEGG:
-
Kyoto encyclopedia of genes and genomes
- GSEA:
-
Gene set enrichment analysis
- TIDE:
-
Tumor immune dysfunction and exclusion
- TAMs:
-
Tumor-associated macrophages
References
Bao R et al (2021) Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer 9:e002417. https://doi.org/10.1136/jitc-2021-002417
Belgiovine C, D’Incalci M, Allavena P, Frapolli R (2016) Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci 73:2411–2424. https://doi.org/10.1007/s00018-016-2166-5
Bernards R, Dessain SK, Weinberg RA (1986) N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47:667–674
Castleberry RP (1997) Neuroblastoma. Eur J Cancer 33:1430–1437
Chandran SS, Klebanoff CA (2019) T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol Rev 290:127–147. https://doi.org/10.1111/imr.12772
Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330. https://doi.org/10.1038/nature21349
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146. https://doi.org/10.1038/nrc3670
DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369–382. https://doi.org/10.1038/s41577-019-0127-6
Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509–8521. https://doi.org/10.1002/jcp.27782
Ford K et al (2020) NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res 80:1846–1860. https://doi.org/10.1158/0008-5472.CAN-19-3158
Hellström IE, Hellström KE, Pierce GE, Bill AH (1968) Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A 60:1231–1238
Iwahori K (2020) Cytotoxic CD8+ lymphocytes in the tumor microenvironment. Adv Exp Med Biol 1224:53–62. https://doi.org/10.1007/978-3-030-35723-8_4
Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R (2010) Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32:91–103. https://doi.org/10.1016/j.immuni.2009.11.010
Lauder I, Aherne W (1972) The significance of lymphocytic infiltration in neuroblastoma. Br J Cancer 26:321–330
Layer JP et al (2017) Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology 6:e1320626. https://doi.org/10.1080/2162402X.2017.1320626
Lenardo M, Rustgi AK, Schievella AR, Bernards R (1989) Suppression of MHC class I gene expression by N-myc through enhancer inactivation. EMBO J 8:3351–3355
Luksch R et al (2016) Neuroblastoma (Peripheral neuroblastic tumours). Crit Rev Oncol Hematol 107:163–181. https://doi.org/10.1016/j.critrevonc.2016.10.001
Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362:2202–2211. https://doi.org/10.1056/NEJMra0804577
Martin RF, Beckwith JB (1968) Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg 3:161–164
Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL (2021) Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol 12:643771. https://doi.org/10.3389/fimmu.2021.643771
Mina M et al (2015) Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology 4:e1019981
Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F (2017) 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer 16:114. https://doi.org/10.1186/s12943-017-0686-8
Modak S, Cheung N-KV (2010) Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36:307–317. https://doi.org/10.1016/j.ctrv.2010.02.006
Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18:85–100. https://doi.org/10.1038/s41571-020-0426-7
O’Neill LAJ, Pearce EJ (2016) Immunometabolism governs dendritic cell and macrophage function. J Exp Med 213:15–23. https://doi.org/10.1084/jem.20151570
Ollé Hurtado M et al (2019) Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. PloS One 14:e0216373. https://doi.org/10.1371/journal.pone.0216373
Otte J, Dyberg C, Pepich A, Johnsen JI (2020) MYCN function in neuroblastoma development. Front Oncol 10:624079. https://doi.org/10.3389/fonc.2020.624079
Pathania AS et al (2022) Immune checkpoint molecules in neuroblastoma: a clinical perspective. Semin Cancer Biol 86:247–258. https://doi.org/10.1016/j.semcancer.2022.06.013
Pathania AS et al (2022) miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma. Mol Ther Oncolytics 25:308–329. https://doi.org/10.1016/j.omto.2022.03.010
Peng Y et al (2021) Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell Int 21:98. https://doi.org/10.1186/s12935-021-01792-4
Petty AJ et al (2019) Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest 129:5151–5162. https://doi.org/10.1172/JCI128644
Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32:79–90. https://doi.org/10.1016/j.immuni.2009.11.012
Podojil JR, Miller SD (2017) Potential targeting of B7–H4 for the treatment of cancer. Immunol Rev 276:40–51. https://doi.org/10.1111/imr.12530
Raffaghello L et al (2005) Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24:4634–4644
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355. https://doi.org/10.1126/science.aar4060
Runa F, Hamalian S, Meade K, Shisgal P, Gray PC, Kelber JA (2017) Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep 3:218–229. https://doi.org/10.1007/s40610-017-0073-7
Saxena M, van der Burg SH, Melief CJM, Bhardwaj N (2021) Therapeutic cancer vaccines. Nat Rev Cancer 21:360–378. https://doi.org/10.1038/s41568-021-00346-0
Shapouri-Moghaddam A et al (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233:6425–6440. https://doi.org/10.1002/jcp.26429
Shi J, Zhang P, Su H, Cai L, Zhao L, Zhou H (2021) Bioinformatics analysis of neuroblastoma miRNA based on GEO data pharmgenomics. Pers Med 14:849–858. https://doi.org/10.2147/PGPM.S312171
Spill F, Reynolds DS, Kamm RD, Zaman MH (2016) Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol 40:41–48. https://doi.org/10.1016/j.copbio.2016.02.007
Szanto CL, Cornel AM, Vijver SV, Nierkens S (2020) Monitoring immune responses in neuroblastoma patients during therapy. Cancers (Basel) 12:519. https://doi.org/10.3390/cancers12020519
van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233. https://doi.org/10.1038/nrc.2016.16
Wienke J, Dierselhuis MP, Tytgat GAM, Künkele A, Nierkens S, Molenaar JJ (2021) The immune landscape of neuroblastoma: challenges and opportunities for novel therapeutic strategies in pediatric oncology. Eur J Cancer 144:123–150. https://doi.org/10.1016/j.ejca.2020.11.014
Yu T, Li L, Liu W, Ya B, Cheng H, Xin Q (2019) Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SH-SY5Y by inhibiting PI3K/Akt-dependent glycolysis. Oncol Res 27:525–532. https://doi.org/10.3727/096504018X15179668157803
Acknowledgements
Not applicable.
Funding
This study was supported by the National Natural Science Foundation of China (Grant No. 82060290), the Natural Science Foundation of Jiangxi Province (Grant No. 20212BAB216040) and the Science and Technology Planed Projects of Jiangxi Provincial Health Commission (Grant No. 202110021).
Author information
Authors and Affiliations
Contributions
LK and CX conceived and designed a specific research plan, BW conducted data analysis, BW, SZP, YXP and CZY wrote original draft. WH and JYQ performed data collection, and LK supervised the manuscript. All authors read and approved the current manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
No potential competing interests was declared by the authors.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Research involving human participants and/or animals
Not applicable.
Informed consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bao, W., Song, Z., Wan, H. et al. Model for predicting prognosis and immunotherapy based on CD+8 T cells infiltration in neuroblastoma. J Cancer Res Clin Oncol 149, 9839–9855 (2023). https://doi.org/10.1007/s00432-023-04897-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-04897-7